



DIA Oligonucleotide-Based Therapeutics Conference

October 25-27 | Bethesda North Marriott Hotel and Conference Center | North Bethesda, MD

Overview

Convening industry and health authorities to inform, educate, and share advancements in oligonucleotide-based therapeutic product development.

This conference brings new thinking about the role and applications of oligonucleotide-based therapeutics in the medical product life cycle, with the intent of an exchange of ideas between FDA, industry, and academia. The conference places an emphasis on the alignment of CMC, Nonclinical, and Clinical knowledge with regulatory and translational science.

Highlights

- **Keynote Speaker:**

- **Philip J. Brooks, PhD**

- Program Director, Division of Clinical Innovation
National Center for Advancing Translational
Sciences (NCATS), National Institutes of Health

- Poster Session
- Leading topics include: mRNA, CRISPR, and Immuno-oncology
 - View the program agenda for this year's full range of forward thinking topics
- Luncheon Round Table Discussions on cutting-edge topics with key thought leaders
- Oligo Safety Working Group (OSWG) open meeting

Who Should Attend

Senior-level professionals and those working in the following areas of oligonucleotide science:

- Drug Discovery
- Preclinical
- Clinical
- CMC
- Quality Assurance
- RNAi
- Vaccines
- Biotechnology
- Delivery Technologies
- Clinical Pharmacology/Research

What You Can Expect

- FDA's current thinking about the regulatory science governing oligo-based therapeutics
- Open, engaged discussions with senior-level regulatory and industry leaders on accepted new concepts and approaches for oligo-based therapeutics
- Exploration of emerging ideas with key thought leaders, FDA speakers, and attendees
- Opportunities for cross-functional communication with related biopharmaceutical disciplines, such as toxicology, pharmacology, clinical research, pharmacovigilance, chemistry, delivery technologies, and many more

“This is a very targeted meeting and a ‘must-attend’ for those developing drugs based on oligonucleotides. It is a multidisciplinary meeting that is well organized and has several new and challenging topics where industry and regulatory agency attendees participate with a view to enabling getting drugs to patients.”

-Previous Attendee

Submit a Poster Abstract!

Submission Deadline: Monday, August 28
Learn more at DIAglobal.org/Oligo17



800 Enterprise Road
Suite 200
Horsham, PA 19044 USA

Learn more at DIAglobal.org/Oligo17